BioSpace News Archive

Today, BlueSphere Bio announced that the Food and Drug Administration (FDA) has cleared BlueSphere’s Investigational New Drug application (IND) for a Phase 1/2a trial (TCX-101) of its first-in-human (BSB-1001) product candidate for patients with relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS), in conjunction with allogeneic hematopoietic stem cell transplantation (alloHSCT).

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting currently being held in Chicago.

Entera Bio Ltd. today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting.

The Leukemia & Lymphoma Society and Institute for Follicular Lymphoma Innovation announce a new partnership on a $20-million initiative to fund research in follicular lymphoma, the most common slow-growing non-Hodgkin’s lymphoma.

Cyclacel Pharmaceuticals, Inc. today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL.

Johnson & Johnson today announced longer-term data from the pivotal Phase 1/2 MajesTEC-1 study of TECVAYLI® (teclistamab-cqyv) showing deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM) who are triple-class exposed (TCE)a and who previously received three or more prior lines of therapy, including in patients who switched to less frequent dosing (Abstract #7540).

Stryker announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures.

AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens.

Debiopharm granted exclusive global rights to use Genome & Company’s antibodies to develop potential first-in-class ADCs integrating Debiopharm’s Multilink™ technology.

ASCO Annual Meeting – Massive Bio and Un Ensayo Para Mi (UEPM), a premier clinical trial search platform in Latin America, are excited to announce an expanded partnership.